Analytical Data
-
Gene name
ARHGAP29
- Application
-
Alternative Names
PARG1; PTPL1-associated RhoGAP protein 1
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8CGF1
-
Expression Region
Ile192~Glu462
-
Molecular Weight
35kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ARHGAP29, a member of the Rho GTPase-activating protein family, plays a critical role in regulating cytoskeletal dynamics and cellular signaling pathways by inactivating Rho GTPases. Its involvement in various biological processes, including cell migration, proliferation, and differentiation, has garnered significant attention in recent years. Notably, studies have linked ARHGAP29 to several human diseases, including cancer and neurological disorders, making it a compelling target for therapeutic interventions. Research into the recombinant expression of ARHGAP29 has advanced our understanding of its structural and functional properties, providing insights into its mechanisms of action. Recombinant ARHGAP29 protein can be utilized in biochemical assays to dissect its interactions with Rho GTPases and other signaling molecules, as well as to explore its potential regulatory roles in cellular contexts. This background enables us to investigate the therapeutic implications of modulating ARHGAP29 activity, highlighting its significance as a molecular target in disease treatment strategies.
